Trials / Terminated
TerminatedNCT04990219
A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis
Interventional, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 1B Study Investigating the Effects of Lu AG06466 for the Treatment of Spasticity in Patients With Multiple Sclerosis
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to investigate Lu AG06466 as a treatment for spasticity in participants with multiple sclerosis (MS).
Detailed description
The participants will be randomized to Lu AG06466 or placebo in a 2:1 ratio.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lu AG06466 | Lu AG06466 - capsule |
| DRUG | Placebo | Placebo - capsule |
Timeline
- Start date
- 2021-09-27
- Primary completion
- 2023-01-19
- Completion
- 2023-01-31
- First posted
- 2021-08-04
- Last updated
- 2023-02-03
Locations
7 sites across 2 countries: United States, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04990219. Inclusion in this directory is not an endorsement.